These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
432 related articles for article (PubMed ID: 26644288)
1. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas. Davis JL; Horvai AE Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288 [TBL] [Abstract][Full Text] [Related]
2. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Conner JR; Hornick JL Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429 [TBL] [Abstract][Full Text] [Related]
3. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Machado I; Navarro S; Picci P; Llombart-Bosch A Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835 [TBL] [Abstract][Full Text] [Related]
4. [Significance of SATB2 in the pathologic diagnosis of osteosarcoma]. Li M; Cai YP; Lu KY; Chen Y; Zhu X; Yin Y; Tang J Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):631-5. PubMed ID: 27646893 [TBL] [Abstract][Full Text] [Related]
5. [Value of MDM2, CDK4 and SATB2 immunohistochemistry in histologic diagnosis of low-grade osteosarcoma]. Chen CY; Zhang HZ; Jiang ZM; Zhou J; Chen J; Liu L Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):387-92. PubMed ID: 27256046 [TBL] [Abstract][Full Text] [Related]
6. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases. Sangoi AR; Kshirsagar M; Horvai AE; Roma AA Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605 [TBL] [Abstract][Full Text] [Related]
7. Osteocalcin and Osteonectin Expression in Canine Osteosarcoma. Wehrle-Martinez AS; Dittmer KE; Aberdein D; Thompson KG Vet Pathol; 2016 Jul; 53(4):781-7. PubMed ID: 26926085 [TBL] [Abstract][Full Text] [Related]
9. SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone. Warmke LM; Maloney N; Leung CH; Lin H; Lazar AJ; Wang WL Am J Clin Pathol; 2022 Aug; 158(2):235-241. PubMed ID: 35311957 [TBL] [Abstract][Full Text] [Related]
10. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma. Ordóñez NG Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906 [TBL] [Abstract][Full Text] [Related]
11. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083 [TBL] [Abstract][Full Text] [Related]
12. BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas With BCOR Genetic Abnormalities. Kao YC; Sung YS; Zhang L; Jungbluth AA; Huang SC; Argani P; Agaram NP; Zin A; Alaggio R; Antonescu CR Am J Surg Pathol; 2016 Dec; 40(12):1670-1678. PubMed ID: 27428733 [TBL] [Abstract][Full Text] [Related]
13. Sclerosing epithelioid fibrosarcoma of bone: morphological, immunophenotypical, and molecular findings of 9 cases. Kosemehmetoglu K; Ardic F; Kilpatrick SE; Aydingoz U; Sumathi VP; Michal M Virchows Arch; 2021 Apr; 478(4):767-777. PubMed ID: 33084978 [TBL] [Abstract][Full Text] [Related]
14. YJ5 as an immunohistochemical marker of osteogenic lineage. Chua K; Virshup DM; Odono EG; Chang KTE; Tan NJH; Hue SS; Sim AYL; Lee VKM Pathology; 2021 Feb; 53(2):229-238. PubMed ID: 33187685 [TBL] [Abstract][Full Text] [Related]
15. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours: comment on Conner et al. (2013). Creytens D; Ferdinande L Histopathology; 2015 Aug; 67(2):272-3. PubMed ID: 25469978 [No Abstract] [Full Text] [Related]
16. Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series. Wojcik JB; Bellizzi AM; Dal Cin P; Bredella MA; Fletcher CD; Hornicek FJ; Deshpande V; Hornick JL; Nielsen GP Am J Surg Pathol; 2014 Nov; 38(11):1538-44. PubMed ID: 24921641 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours. Strickland S; Parra-Herran C Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609 [TBL] [Abstract][Full Text] [Related]
18. SOX9 and SATB2 immunohistochemistry cannot reliably distinguish between osteosarcoma and chondrosarcoma on biopsy material. Sharma AE; Pytel P; Cipriani NA Hum Pathol; 2022 Mar; 121():56-64. PubMed ID: 35016891 [TBL] [Abstract][Full Text] [Related]
19. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics. Jiang L; Liu J; Wei Q; Wang Y Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814 [TBL] [Abstract][Full Text] [Related]
20. MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Dujardin F; Binh MB; Bouvier C; Gomez-Brouchet A; Larousserie F; Muret Ad; Louis-Brennetot C; Aurias A; Coindre JM; Guillou L; Pedeutour F; Duval H; Collin C; de Pinieux G Mod Pathol; 2011 May; 24(5):624-37. PubMed ID: 21336260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]